Azvudine beats paxlovid in reducing COVID-19 deaths In hospitalized COVID-19 patients, azvudine shows lower all-cause mortality and fewer adverse events than Paxlovid, with added antitumor effects observed. Vijay Kumar Malesu News-Medical

In a recent study published in the Signal Transduction and Targeted Therapy, a group of researchers compared the effectiveness and safety of azvudine versus nirmatrelvir-ritonavir (Paxlovid) in hospitalized coronavirus disease 2019 (COVID-19) patients, with a focus on clinical outcomes, adverse events (AEs), and potential benefits for patients with malignant tumors.

...